Navigation Links
Callisto Reports on Second-Quarter 2007 Milestones
Date:8/19/2007

Company Cites Continuing Progress on Clinical and Preclinical Programs

NEW YORK, Aug. 8 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal diseases, is pleased to provide an update covering its strategic and drug development activities for the second quarter of 2007.

"Callisto has made substantial progress with our clinical and preclinical programs in 2007," stated Gary S. Jacob, CEO of Callisto Pharmaceuticals. "In particular, the pace of our Phase II clinical trial of Atiprimod in neuroendocrine cancer patients continues to go well, and we expect to have full enrollment accomplished by the third quarter of 2007. "

The Atiprimod Phase II clinical trial in neuroendocrine carcinoma is a multiple-center, open-label study of the safety and efficacy of Atiprimod in low to intermediate grade neuroendocrine carcinoma patients. The trial, designed to enroll 40 patients, presently has 29 patients on study, and Callisto anticipates achieving the total enrollment of 40 patients in the third quarter of 2007. The trial was opened in November, 2006 and there are presently 5 clinical sites in the U.S. that are enrolling patients. The Company plans to have discussions with FDA some time in the fourth quarter of 2007 regarding the design of a pivotal trial in this disease indication.

Dr. Jacob continued, "We also have implemented a plan to develop Guanilib, Callisto's guanylyl cyclase C receptor agonist, to treat gastrointestinal disorders such as chronic constipation and irritable bowel syndrome. We plan to file an Investigational New Drug application with FDA in early 2008, and evaluate its potential initially in gastrointestinal disorders where there is a critical need for new drugs to treat the millions of patients currently suffering from these maladies."

About Guanilib

Guanilib (also called SP-304) is a potent analog (synt
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 Shire ... today that it has acquired New ... for $300 million. With the acquisition, Shire acquires ... combining 0.6% povidone iodine (PVP-I) and 0.1% dexamethasone), ... of infectious conjunctivitis, an ocular surface condition commonly ...
(Date:8/2/2015)... , Aug. 3, 2015  Lexicon Pharmaceuticals, ... the pivotal TELESTAR Phase 3 clinical trial met ... telotristat etiprate in treating cancer patients with carcinoid ... current standard of care. Telotristat etiprate was discovered ... technology, and is the company,s first discovery to ...
(Date:7/31/2015)... -- More than 1,500 substance abuse prevention and treatment ... Indianapolis Aug. 2-6 for Community Anti-Drug ... . The week-long training, held at the JW Marriott, ... nation,s biggest public health challenges – youth drug use. ... one-of-a-kind intensive training opportunity, offering more than 70 half-day ...
Breaking Medicine Technology:Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Medical AB ( http://www.omxgroup.com, OMX: DIAM B; ... http://www.otcqx.com, OTC: ... B)(OTC: DMYDY)announced today that the Swedish Medical Products,Agency (MPA) has ... therapeutic diabetes vaccine Diamyd(R)., (Logo: http://www.newscom.com/cgi-bin/prnh/20080314/297194 ), ...
... Onset with SYMBICORT with Improved Lung Function within ... ... WILMINGTON, Del., March 18 Data from a new,study demonstrated ... greater,and faster bronchodilatory effects, or opening of the airways, compared,with ...
Cached Medicine Technology:Diamyd(R) Diabetes Vaccine Receives Approval to Start Phase III Trials in Europe 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 2Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 3Study Compares Bronchodilatory Effects of SYMBICORT(R) and Advair in Adults With Asthma 4
(Date:8/3/2015)... ... 2015 , ... A July 9 article from USA Today has ... to the American Dental Association. According to a study by the American Dental Association, ... in a single year to 2.2 million a year. Dentists and ADA officials all ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number ... according to market research compiled for the National Association of Dental Laboratories ( ... Labor, Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
(Date:8/3/2015)... ... 2015 , ... Constantin Vasilica, 48 from Romania wanted to have an alternative ... many years of suffering and using medications with strong side effects. This had already ... extra time off or wait longer hours in the waiting rooms. Instead, he went ...
(Date:8/3/2015)... ... August 03, 2015 , ... Foot and Ankle ... new associate podiatrist, creating the largest medical practice in the Mid-Atlantic region – and ... FASMA operates 21 locations with 33 doctors. , Dr. Hetal Kathrotiya-Mago is a Maryland ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 2Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 3Health News:Leading Foot and Ankle Medical Practice Adds Three New Podiatrists 4
... , , , ... Governor Schwarzenegger line-item vetoed the Department of Public Health,s ... shelters and centers. , , Services provided ... with restraining orders, counseling and other vital support services. ...
... , , , ... weight management industry, announced today their "Less Is More" campaign, which ... lives and the lives of others through simple, every day thoughtful ... major cities across the country on September 26, 2009 with the ...
... , , , TREVOSE, Pa., ... ) the nation,s largest Italian Ice concept with more than ... $451,000 this June for Alex,s Lemonade Stand Foundation for Childhood Cancer ... of June for the past four years, Rita,s has collectively raised ...
... consisted of 10 patients (three male and seven female) ... years (age range, 19-78 years). Of these patients, dynamic ... with intratumoral fatty density, absence of a capsule, and ... small hepatic angiomyolipomas, with or without a fat component ...
... , , DEERFIELD ... found a promising solution that puts power back in the healthcare ... in an upcoming episode of the show,s series on Solutions for ... http://www.newscom.com/cgi-bin/prnh/20080206/AQW030LOGO-b ) , , The days when ...
... , LIVONIA, Mich., July 30 American ... Individual health insurance, announced today that it has introduced its ... Provider Network will save policyholders an average of 5 percent ... remains committed to ensuring that policyholders have the freedom and ...
Cached Medicine News:Health News:Governor Eliminates Funding to Domestic Violence Programs 2Health News:Metabolife(R) Reminds Us That the Little Things We Do Can Bring Positive Change to Our Lives and the Lives of Others 2Health News:Rita's Squeezes Pediatric Cancer with $451,000 Donation 2Health News:Rita's Squeezes Pediatric Cancer with $451,000 Donation 3Health News:Healthcare: Solutions for the American Crisis 'The Economic Report' Show to Feature Rising Medical Solutions, Inc. 2Health News:Healthcare: Solutions for the American Crisis 'The Economic Report' Show to Feature Rising Medical Solutions, Inc. 3Health News:American Community Introduces Its Own PPO Network in Ohio to Save Policyholders Money 2
... Microscope with excellent maneuverability. Konan ... weight maintaining high quality. Easy ... by simply changing the adapter. ... has resulted in a sharp ...
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Instrument necessary for insertion of Ritleng Bicanaliculus systems and of Self-Threading Monoka systems....
Medicine Products: